Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Addex Therapeutics FY23 EPS CHF (0.14) Up From CHF (0.46) YoY, Income CHF 1.65M Up From CHF 1.45M YoY

Author: Benzinga Newsdesk | April 18, 2024 02:03am

Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024
Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical portfolio
Received CHF 5 million upfront and 20% equity in Neurosterix, providing cash runway beyond 2026

Posted In: ADXN